Top-Rated StocksTop-RatedNASDAQ:CGON CG Oncology (CGON) Stock Price, News & Analysis $26.31 -0.38 (-1.42%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$26.50 +0.20 (+0.74%) As of 08/1/2025 05:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About CG Oncology Stock (NASDAQ:CGON) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CG Oncology alerts:Sign Up Key Stats Today's Range$25.73▼$26.6350-Day Range$24.95▼$28.4652-Week Range$14.80▼$40.47Volume815,524 shsAverage Volume977,843 shsMarket Capitalization$2.01 billionP/E RatioN/ADividend YieldN/APrice Target$55.30Consensus RatingBuy Company Overview CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California. Read More CG Oncology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks38th Percentile Overall ScoreCGON MarketRank™: CG Oncology scored higher than 38% of companies evaluated by MarketBeat, and ranked 685th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingCG Oncology has received a consensus rating of Buy. The company's average rating score is 3.08, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCG Oncology has only been the subject of 3 research reports in the past 90 days.Read more about CG Oncology's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for CG Oncology are expected to decrease in the coming year, from ($1.31) to ($1.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CG Oncology is -17.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CG Oncology is -17.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCG Oncology has a P/B Ratio of 2.73. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about CG Oncology's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted24.02% of the float of CG Oncology has been sold short.Short Interest Ratio / Days to CoverCG Oncology has a short interest ratio ("days to cover") of 8.6.Change versus previous monthShort interest in CG Oncology has recently decreased by 4.52%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCG Oncology does not currently pay a dividend.Dividend GrowthCG Oncology does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted24.02% of the float of CG Oncology has been sold short.Short Interest Ratio / Days to CoverCG Oncology has a short interest ratio ("days to cover") of 8.6.Change versus previous monthShort interest in CG Oncology has recently decreased by 4.52%, indicating that investor sentiment is improving. News and Social Media2.7 / 5News Sentiment0.83 News SentimentCG Oncology has a news sentiment score of 0.83. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.63 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for CG Oncology this week, compared to 5 articles on an average week.MarketBeat Follows4 people have added CG Oncology to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, CG Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $56,000.00 in company stock.Percentage Held by InsidersOnly 7.40% of the stock of CG Oncology is held by insiders.Percentage Held by InstitutionsOnly 26.56% of the stock of CG Oncology is held by institutions.Read more about CG Oncology's insider trading history. Receive CGON Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CG Oncology and its competitors with MarketBeat's FREE daily newsletter. Email Address CGON Stock News HeadlinesCG Oncology, Inc. (NASDAQ:CGON) Director Leonard E. Post Sells 2,000 SharesJuly 19, 2025 | insidertrades.comCG Oncology, Inc. (CGON) Reports 75.5% Complete Response in Bladder Cancer TrialJuly 31 at 6:32 PM | msn.comEx-Hedge Fund Manager Uncovers $100 Trillion Land ShiftTrump's Radical New Plan Could Enrich Thousands This isn't a campaign stunt. It's a $100 trillion move to unlock federal lands, oil reserves, and buried minerals... all for profit. Trump's team is already executing the orders... and Wall Street legend Whitney Tilson is stepping forward to show you how to position before the deadline. | Stansberry Research (Ad)1CGON : Beyond The Numbers: 7 Analysts Discuss CG Oncology StockJuly 16, 2025 | benzinga.comCGON - CG Oncology Inc Trailing Returns - MorningstarJune 26, 2025 | morningstar.comMCG Oncology: Looking Undervalued Heading Toward FDA Submission (Upgrade)June 23, 2025 | seekingalpha.comCG Oncology stock price target raised to $56 from $52 at Morgan StanleyJune 18, 2025 | investing.comAugust 15th Options Now Available For CG Oncology (CGON)June 18, 2025 | nasdaq.comSee More Headlines CGON Stock Analysis - Frequently Asked Questions How have CGON shares performed this year? CG Oncology's stock was trading at $28.68 at the beginning of 2025. Since then, CGON stock has decreased by 8.3% and is now trading at $26.31. How were CG Oncology's earnings last quarter? CG Oncology, Inc. (NASDAQ:CGON) posted its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.45) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by $0.09. The company earned $0.05 million during the quarter, compared to the consensus estimate of $0.53 million. CG Oncology had a negative trailing twelve-month return on equity of 16.71% and a negative net margin of 15,945.17%. When did CG Oncology IPO? CG Oncology (CGON) raised $380 million in an initial public offering on Thursday, January 25th 2024. The company issued 20,000,000 shares at $19.00 per share. Who are CG Oncology's major shareholders? CG Oncology's top institutional investors include TD Asset Management Inc (0.27%), AMI Asset Management Corp (0.05%), Wesbanco Bank Inc. (0.04%) and CWM LLC (0.01%). Insiders that own company stock include Hong Fang Song, Decheng Capital Global Life Sc, Corleen M Roche, Vijay Kasturi and Leonard E Post. View institutional ownership trends. How do I buy shares of CG Oncology? Shares of CGON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CG Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that CG Oncology investors own include Invesco QQQ (QQQ), SPDR Dow Jones Industrial Average ETF Trust (DIA), SPDR S&P 500 ETF Trust (SPY), Meta Platforms (META), Advanced Micro Devices (AMD), NVIDIA (NVDA) and Tesla (TSLA). Company Calendar Last Earnings5/13/2025Today8/01/2025Next Earnings (Estimated)8/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CGON Previous SymbolNASDAQ:CGON CIK1991792 Webcgoncology.com Phone949-419-6203FaxN/AEmployees61Year FoundedN/APrice Target and Rating Average Price Target for CG Oncology$55.30 High Price Target$75.00 Low Price Target$23.00 Potential Upside/Downside+110.2%Consensus RatingBuy Rating Score (0-4)3.08 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($1.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$88.04 million Net Margins-15,945.17% Pretax Margin-15,945.17% Return on Equity-16.71% Return on Assets-16.24% Debt Debt-to-Equity RatioN/A Current Ratio30.97 Quick Ratio30.97 Sales & Book Value Annual Sales$662 thousand Price / Sales3,029.43 Cash FlowN/A Price / Cash FlowN/A Book Value$9.63 per share Price / Book2.73Miscellaneous Outstanding Shares76,225,000Free Float70,584,000Market Cap$2.01 billion OptionableOptionable Beta0.86 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:CGON) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CG Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CG Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.